4820 Tolazamide A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. 1156-19-0 5503 C14H21N3O3S White powder. 170-173°C 65.4 mg/L (at 30°C) Rapidly and well absorbed from the gastrointestinal tract. Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%. Route of Elimination: Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine. Half Life: The average biological half-life of the drug is 7 hours. No indication of carcinogenicity to humans (not listed by IARC). For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. Overdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. 2014-09-11T05:15:40Z 2014-12-24T20:26:56Z Tolazamide 156131 DB00839 true CC1=CC=C(C=C1)S(=O)(=O)NC(O)=NN1CCCCCC1 C14H21N3O3S InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18) InChIKey=OUDSBRTVNLOZBN-UHFFFAOYSA-N 311.4 311.130362243 Exogenous Solid 2.69 HMDB14977 CHEMBL817 5302